An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Inclusion Criteria:
Exclusion Criteria:
Akashi-shi, Hyōgo 6738558, Japan
Habikino-shi, Osaka 5838588, Japan
Hirakata-shi, Osaka 5731191, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Bunkyo-ku, Tokyo 1138431, Japan
Chuo-ku, Tokyo 1040045, Japan
Chuo-ku, Tokyo 5418567, Japan
Romania, 400015, Romania
Timisoara, Timis, 300239, Romania